Dynamic ECG Centralization is the most agile platform for cardiac safety assessment in Phase II-IV trials. It can save up to 25% in costs compared with traditional methods, and also accelerate the subject recruitment process through the dynamic review of screening ECGs, which leads to a lower rate of false exclusions.

Learn About theiCardiac Advantage

News

Understanding the Implications of the 2014 IQ-CSRC Study on Assessing QT from Data Obtained in First–In-Human Studies

The definitive validation study results were announced at an FDA meeting in December 2014. The study creates a path for sponsors to successfully apply for waivers from stand-alone TQT studies and provides other benefits to sponsors. For complete information and White Paper download visit www.earlyprecisionqt.com.